SENISCA
United Kingdom
- Exeter, Devon
- 19/03/2024
- Unknown
- $4,694,134
SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics).
Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence. This innovation works by restoring the ability of cells to ‘fine tune’ the expression of their genes to rejuvenate aged cells.
At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation of oligonucleotide-based interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing.
- Industry Biotechnology
- Website https://www.senisca.com/
- LinkedIn https://www.linkedin.com/company/senisca/
VerbaFlo.AI | $7,000,000 | (Mar 18, 2026)
Surf AI(1) | $57,000,000 | (Mar 18, 2026)
R1 Therapeutics | $77,500,000 | (Mar 18, 2026)
Quorus | $5,000,000 | (Mar 18, 2026)
BambooBox | $6,600,000 | (Mar 18, 2026)
iDEL Therapeutics GmbH | $10,381,635 | (Mar 18, 2026)
Conduit Health | $17,000,000 | (Mar 18, 2026)
SEQUENTIAL | $3,500,000 | (Mar 18, 2026)
Standard Template Labs | $49,000,000 | (Mar 18, 2026)
Tenkara | $7,000,000 | (Mar 18, 2026)
Turquoise(US) | $40,000,000 | (Mar 18, 2026)
AgZen | $10,000,000 | (Mar 17, 2026)